Hearing Date Set in Blue Calypso Lawsuit Against LivingSocial

Blue Calypso Inc. (OTCBB: BCYP), an innovator in digital social advertising, mobile content syndication, and analytics, recently announced a Markman hearing set for August 27, 2013 in its patent infringement case against LivingSocial. Findings from this hearing may encourage settlements or provide insight into the likelihood of a particular outcome.

With the success seen by companies like Vringo Inc. (AMEX: VRNG) in their lawsuit against AOL Inc. (NYSE: AOL) and VirnetX (ASE: VHC) in their case against Apple Inc. (NASDAQ: AAPL), Blue Calypso is a stock worth watching closely as this date approaches. Successful litigation could set the stage for similar outcomes against many other companies in the space.

“We believe that there may be a significant and growing number of companies infringing our patents. We intend to pursue every legal remedy at our disposal to protect our core intellectual property and have initially targeted companies that are leaders in various business segments where we compete. A successful outcome would prove out the value of our intellectual property portfolio and validate the market potential of Blue Calypso’s technologies,” said Bill Ogle, Chairman and Chief Executive Officer of Blue Calypso in the recent press release.

Companies in this situation, depending on the results of the Markman hearing, will often settle out of court rather than endure the time and expense of extended litigation. Terms of these settlements often include licensing agreements that allow the company being sued to continue using the technology in exchange for ongoing fees. In this case against LivingSocial, as well as the pending cases against Groupon, Foursquare, Yelp, IZEA and MyLikes, Blue Calypso shareholders would likely benefit greatly from such an arrangement.

“We are confident that Claim Construction Hearings will be scheduled for each of these cases toward the end of 2013, with full jury trials expected in mid-2014, if licensing agreements or other remediation is not achieved prior to litigation,” added Mr. Ogle in the press release, when discussing the actions against other companies in the space.

These cases are being represented by recognized leaders in patent protection and litigation, including Farney Daniels P.C. in its claim against LivingSocial, and Fish & Richardson P.C. in its claims against Groupon, Foursquare, Yelp, IZEA and MyLikes.

Blue Calypso (BCYP) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Cellceutix Targeting Gram-Negative and Candida Fungal Infections

Cellceutix Targeting Gram-Negative and Candida Fungal Infections(0)

Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally - and taking the headline - the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.